Medical devices for shunts, occluders, fenestrations and related systems and methods

An implantable medical device comprising a first frame portion, a second frame portion arranged within the first frame portion and a plurality of diverging elements connecting the first frame portion to the second frame portion.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
CROSS-REFERENCE TO RELATED APPLICATION

This application claims the benefit of Provisional Application No. 62/777,931, filed Dec. 11, 2018, which is incorporated herein by reference in its entirety for all purposes.

FIELD

The present disclosure relates generally to implantable medical devices, and more specifically to implantable medical devices for shunting and/or occluding bodily fluids or structures and related systems and methods thereof.

BACKGROUND

Heart failure and diseases of the heart affect millions of people worldwide. Heart failure includes failure of either the left side of the heart, the right side of the heart, or both. Diseases of the heart that can lead to heart failure include hypertension, pulmonary arterial hypertension, and congenital defects of the heart. The constantly evolving nature of heart failure represents a significant challenge for the treatment methods. Therefore, there is a need for new and adaptable methods and devices for treating heart failure.

SUMMARY

In one example (“Example 1”), an implantable medical device includes a first frame portion having at least three lobes; a second frame portion arranged within the first frame portion; and a plurality of diverging elements arranged between the first frame portion and the second frame portion, the plurality of diverging elements diverge from the first frame portion and the second frame portion to form a central frame with at least six diverging points in a deployed configuration.

In another example (“Example 2”), further to the device of Example 1, the first frame portion and the second frame are contiguous with one another.

In another example (“Example 3”), further to the device of any one of Examples 1-2, the opening is hexagonal in shape when the device is in a deployed configuration.

In another example (“Example 4”), further to the device of any one of Examples 1-3, the first frame portion is located on a first side of a septum, the second frame portion is located on a second side of the septum, and the plurality of diverging elements form a fluid flow path therethrough.

In another example (“Example 5”), further to the device of 4, the first and second frame portions are sufficiently flexible to conform to an anatomy of the septum.

In another example (“Example 6”), further to the device of any one of Examples 1-5, the second frame portion includes at least three lobes.

In another example (“Example 7”), further to the device of any one of Examples 1-6, the first frame portion has a first geometry and the second frame portion has a second geometry that is different from the first geometry.

In another example (“Example 8”), further to the device of any one of Examples 1-7, the first frame portion includes six lobes.

In another example (“Example 9”), further to the device of any one of Examples 1-8, each of the lobes of the second frame portion comprises an eyelet configured to aid in delivery of the device.

In another example (“Example 10”), further to the device of any one of Examples 1-9, the device also includes a covering material arranged on at least a portion of the device.

In another example (“Example 11”), further to the device of 10, the first frame portion includes the covering material and the second frame portion is free of the covering material.

In another example (“Example 12”), further to the device of 11, the covering material includes expanded polytetrafluoroethylene (ePTFE).

In another example (“Example 13”), further to the device of any one of Examples 1-12, the first frame portion and the second frame portion are unitary such that the device is formed of a single wire.

In another example (“Example 14”), further to the device of any one of Examples 1-13, the device also includes a sensor arranged with the conduit portion or the frame component and configured to sense at least one of physiologic properties, hemodynamics, biomarkers, sound, pressure, and electrolytes

In another example (“Example 15”), further to the device of any one of Examples 1-14, the device also includes at least one of a coating of heparin to facilitate thromboresistance and patency of the device and a coating of paclitaxel to modulate tissue/cellular response.

In one example (“Example 16”), an implantable medical device for regulating blood pressure between a left atrium and a right atrium of a heart, the device having a delivery configuration and a deployed configuration includes a first frame portion; a second frame portion arranged within the first frame portion; and a plurality of diverging elements connecting the first frame portion to the second frame portion, the plurality of diverging elements form a central portion having an opening, and wherein the opening is substantially hexagonal in shape when the device is in the deployed configuration.

In another example (“Example 17”), further to the device of Example 16, each of the plurality of diverging elements overlaps one another to form diverging points, and wherein the diverging points expand outward when the device is in the deployed configuration to form the hexagonal shape.

In another example (“Example 18”), further to the device of Example 16, the first frame portion and the second frame portion are coplanar with one another when the device is in the deployed configuration, and are nonplanar with one another when the device is in the delivery configuration.

In one example (“Example 19”), a method of making the implantable medical device of any one of Examples 1 to 18 includes cutting a two-dimensional pattern out of a nitinol sheet.

In one example (“Example 20”), a method for regulating blood pressure between a left atrium and a right atrium of a heart includes delivering an implantable medical device to a desired treatment location within a body of a patient while the device is in a delivery configuration; positioning a first frame portion of the device on a first side of a septum; positioning a second frame portion of the device on a second side of the septum; and releasing the device from the delivery configuration to a deployed configuration such that a central portion of the device forms an opening that is substantially hexagonal in shape.

In another example (“Example 21”), further to the method of 20, the method also includes expanding the central portion to adjust a rate of fluid flow therethrough.

In one example (“Example 22”), an implantable medical device includes a first frame portion having at least two lobes; a second frame portion having at least two lobes; and a plurality of diverging elements arranged between the first frame portion and the second frame portion, the plurality of diverging elements diverge from the first frame portion and the second frame portion to form a central frame that is configured to approximate a circular shape in a deployed configuration.

In another example (“Example 23”), further to the medical device of Example 22, the central frame includes a polygonal structure configured to approximate the circular shape in the deployed configuration.

In another example (“Example 24”), further to the medical device of Example 22, the two lobes of the first frame portion are configured to conform to a first tissue surface and the two lobes of the second frame portion are configured to conform to a second tissue surface.

In another example (“Example 25”), further to the medical device of Example 22, the first and second frame portions are sufficiently flexible to conform to an anatomy of the septum.

The foregoing Examples are just that, and should not be read to limit or otherwise narrow the scope of any of the inventive concepts otherwise provided by the instant disclosure. While multiple examples are disclosed, still other embodiments will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative examples. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature rather than restrictive in nature.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings are included to provide a further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments, and together with the description serve to explain the principles of the disclosure.

FIG. 1 is an example implantable medical device for regulating blood pressure, in accordance with an embodiment;

FIG. 2 is a perspective view of an implantable medical device, in accordance with an embodiment;

FIG. 3 is a top view of a first side of an implantable medical device, in accordance with an embodiment;

FIG. 4 is a top view of another implantable medical device, in accordance with an embodiment;

FIG. 5 is a top view of another implantable medical device, in accordance with an embodiment;

FIG. 6 is a top view of a first side of another implantable medical device, in accordance with an embodiment.

FIG. 7 is a perspective view of another implantable medical device, in accordance with an embodiment;

FIG. 8A is an image of a first side of an implantable medical device, in accordance with an embodiment;

FIG. 8B is an image of a second side of the implantable medical device of FIG. 7A, in accordance with an embodiment;

FIG. 9A is an image of an implantable medical device, in accordance with an embodiment;

FIG. 9B is an image of a first side of the implantable medical device of FIG. 9A, with a membrane, in accordance with an embodiment;

FIG. 9C is an image of a second side of the implantable medical device of FIGS. 9A-B, in accordance with an embodiment;

FIG. 10A is an image of an implantable medical device, in accordance with an embodiment;

FIG. 10B is an image of the implantable medical device of FIG. 10A having an open central portion, in accordance with an embodiment;

FIG. 11 is an image of another implantable medical device, in accordance with an embodiment;

FIG. 12 is an image of another implantable medical device, in accordance with an embodiment;

FIG. 13 is an image of an implantable medical device and a deployment apparatus, in accordance with an embodiment;

FIG. 14A is an image of an implantable medical device and a deployment apparatus, in accordance with an embodiment;

FIG. 14B is an image of the implantable medical device with a first side deployed from the delivery apparatus shown in FIG. 14A, in accordance with an embodiment;

FIG. 15A is an image of the implantable medical device, shown in FIG. 5, in accordance with an embodiment.

FIG. 15B is an image of the implantable medical, shown in FIG. 15A, including a covering material, in accordance with an embodiment;

FIG. 15C is an image of a first side of the implantable medical device, shown in FIG. 15A, with a membrane, in accordance with an embodiment;

FIG. 15D is an image of a second side of the implantable medical device, shown in FIGS. 15B-C, in accordance with an embodiment;

FIG. 16A is an image of an implantable medical device, in accordance with an embodiment;

FIG. 16B is an image of a second configuration of the implantable medical shown in FIG. 16A, in accordance with an embodiment;

FIG. 16C is an image of the implantable medical device, shown in FIG. 16A, in a deployed configuration in accordance with an embodiment;

FIG. 17A is an image of an implantable medical device, in accordance with an embodiment;

FIG. 17B is an image of the implantable medical device, shown in FIG. 17A, in a deployed configuration, in accordance with an embodiment.

FIG. 18 is an illustration of an implantable medical device, in accordance with an embodiment.

FIG. 19 is an illustration of an implantable medical device, in accordance with an embodiment.

 DETAILED DESCRIPTION Definitions and Terminology

This disclosure is not meant to be read in a restrictive manner. For example, the terminology used in the application should be read broadly in the context of the meaning those in the field would attribute such terminology.

With respect to terminology of inexactitude, the terms “about” and “approximately” may be used, interchangeably, to refer to a measurement that includes the stated measurement and that also includes any measurements that are reasonably close to the stated measurement. Measurements that are reasonably close to the stated measurement deviate from the stated measurement by a reasonably small amount as understood and readily ascertained by individuals having ordinary skill in the relevant arts. Such deviations may be attributable to measurement error, differences in measurement and/or manufacturing equipment calibration, human error in reading and/or setting measurements, minor adjustments made to optimize performance and/or structural parameters in view of differences in measurements associated with other components, particular implementation scenarios, imprecise adjustment and/or manipulation of objects by a person or machine, and/or the like, for example. In the event it is determined that individuals having ordinary skill in the relevant arts would not readily ascertain values for such reasonably small differences, the terms “about” and “approximately” can be understood to mean plus or minus 10% of the stated value.

Description of Various Embodiments

Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatuses configured to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.

Various aspects of the present disclosure are directed toward implantable medical devices such as devices for shunting and/or occluding bodily fluids or structures. In certain instances, the various aspects of the present disclosure relate to methods and devices for treating heart failure by reducing elevated blood pressure in a heart chamber by creating a pressure relief shunt. Additionally, some embodiments relate to methods and devices for customizing, adjusting or manipulating the flow of blood through the shunt in order to enhance the therapeutic effect of the pressure relief shunt. In some instances, the devices disclosed herein retain patency within the patient's body by reducing shear forces around the heart.

FIG. 1 is an example implantable medical device for regulating blood pressure implanted in a patient's body, in accordance with an embodiment. The device 100 is shown implanted within a heart H of the patient. The device 100 is shown arranged between the patient's left atrium LA and right atrium RA. In certain instances, the device 100 may be used to regulate blood flow within the heart H, for example, between the left and right atriums LA, RA. As shown, the device 100 generally includes a first frame portion 110 arranged on a first side of a septum (e.g., within the left atrium LA), a second frame portion 120 arranged on a second side of the septum (e.g., within the right atrium RA), and a central portion 130 extending through the septum. A needle may be used to create an opening in the septum.

A sheath 140 and constraining and/or release lines (not shown) may be used to facilitate deployment of the device 100. For example, a first side of the device 100 that includes the first frame portion 110 may be released after the sheath 190 is advanced through the septum and to the LA, and a second side of the device 100 that includes the second frame portion 120 may be released second on the RA side of the septum. The central portion 130 (e.g., shown in FIG. 2) is arranged within the opening. The first and second frame portions 110, 120 and the central portion 130 may be compressed within the sheath 190 to a delivery configuration such that the first and second frame portions 110, 120 are nonplanar with one another during delivery of the device 100 to the desired treatment area within the patient. The first and second frame portions 110, 120 may be subsequently expanded to a deployed configuration during deployment of the device 100 such that the first and second frame portions 110, 120 are coplanar with one another.

FIG. 2 is a perspective view of an implantable medical device 200 in the deployed configuration, in accordance with an embodiment. As described herein, the device includes the first frame portion 210 and the second frame portion 220. The first and second frame portions 210, 220 are sufficiently flexible to conform to the anatomy of the patient at the desired treatment location. For example, the first frame portion 210 can conform to the first side of the patient's septum (e.g., within the left atrium) and the second frame portion 220 can conform to the second side of the patient's septum (e.g., within the right atrium) as shown in FIG. 1. In some instances, the first frame portion 210 and second frame portion 220 include a first plurality of lobes 212 and a second plurality of lobes 222, respectively. In some instances, the first and second frame portions 210, 220 may include the same number of lobes or a different number of lobes as desired. For example, the first and second frame portions 210, 220 can both include two lobes, three lobes or four or more lobes as desired. As shown in FIG. 6 and FIGS. 9A-C, for example, the frame portions each include two lobes. In another example, the first frame portion 210 includes two lobes while the second frame portion 220 includes three or more lobes, and so on. The first and second frame portions 210, 220 can have any number of lobes as desired. In general, the number of lobes of the first and second frame portions 210, 220 can depend on the anatomy of the patient and the desired treatment location within the patient's body, among other factors.

The first and second frame portions 210, 220 can have a variety of geometries (e.g., shapes, sizes, lobe configurations, etc.). For example, in some instances, the first plurality of lobes 212 of the first frame portion 210 may have a first geometry while the second plurality of lobes 222 of the second frame portion 220 may have a second geometry that is different from the first geometry. For example, the first plurality of lobes 212 can be rhomboid in shape while the second plurality of lobes 222 can be rounded or petal-like. In another example, the first plurality of lobes 212 may be larger than the second plurality of lobes 222 and vice versa. In other instances, the first and second frame portions 210, 220 may have the same or substantially similar geometries. For example, the first and second frame portions 210, 220 can be substantially symmetrical.

As shown in FIG. 2, diverging elements 240 are arranged between the first and second frame portions 210, 220. In certain instances, the diverging elements 240 and the first and second frame portions 210, 220 are contiguous portions of a frame. In some instances, the diverging elements 240 are unitary with the first frame portion 210 and second frame portion 220. The diverging elements 240 are generally elongate members configured to span the septum of the patient and form the central portion 230 of the device 200 and a fluid flow path therethrough in a deployed configuration. For example, the first and second frame portions 210, 220 and the diverging elements 240 may be formed of a single wire. In other terms, the first and second frame portions 210, 220 are contiguous with one another.

In some instances, the diverging elements 240 cross over one another at certain locations in the central portion 230 to form diverging points 242. For example, in certain instances, the diverging elements 240 form at least six diverging points 242, which help to define an opening 250 through the device 200 or tissue. As detailed below, the device 200 may include a covering material 270. In instances where the device 200 does not have the covering material 270, the frame 200 may create and hold opening an opening 250 in tissue. In instances where the frame 200 includes the covering material 270, the opening 250 may be considered to be a portion of the device 200 with the covering material 270 forming the opening 250 or fluid pathway. The diverging points 242 also provide support and rigidity to the central portion 230 when the device 200 is in the deployed configuration. The diverging points 242 generally define an opening 250 that is hexagonal in shape, for example, when there are six diverging points 242 (e.g., each diverging point 242 forming a corner of the hexagon). However, the shape of the opening 250 (e.g., opening in tissue or device 200) will depend on the number of diverging points 242 within the central portion 230. For example, a device 200 having four diverging points 242 may have an opening 250 that is substantially rectangular in shape, or a device 200 having eight diverging points 242 may have an opening 250 that is octagonal in shape.

In some instances, the device 200 can be formed of a single wire. For example, the first and second frame portions 210, 220 and diverging elements 240 can be formed by wrapping a single wire (e.g., a Nitinol or stainless steel wire) in a desired shape or pattern. In some instances, the device 200 can be formed of a single sheet of flexible and biocompatible material. For example, a two-dimensional pattern may be cut from a flat sheet of Nitinol, stainless steel, or non-metallic material. In some instances, where a non-metallic material is used, the device 200 could be resorbable or biodegradable.

In some instances, the device 200 also includes a covering material 270. The covering material 270 may be, for example, a membrane material capable of promoting tissue ingrowth. In some instances, the membrane may also be configured to lessen erosion of the first frame portion 210 and/or the second frame portion 220. For example, the covering material 270 may be polytetrafluoroethylene (ePTFE) or any other suitable biocompatible material (e.g., polymeric or synthetic materials or woven materials).

In some instances, the covering material 270 covers at least a portion of the first frame portion 210 and/or at least a portion of the second frame portion 220. In some instances, both the first and second frame portions 210, 220 are completely covered by the covering material 270. In these instances, the covering material 270 may span the central portion 230. In some instances, the first frame portion 210 may include a first membrane material and the second frame portion 220 may include a second membrane material that is different from the first membrane material. In these instances, the first and second membrane materials may be coupled together at the central portion 230.

In some instances, the covering material 270 can be perforated to facilitate filtration and/or fluid flow through the device 200 to, for example, reduce the risk of stroke in certain patients. However, in other instances, where less fluid flow is desired, the covering material 270 may reduce or prevent fluid flow therethrough.

In certain instances, portions of the covering material 270 may be configured to inhibit tissue ingrowth (e.g., within the opening 250 through the device 200). In addition, portions of the covering material 270 arranged on the first plurality of lobes 212 and/or the second plurality of lobes 222 may be configured to facilitate tissue ingrowth to enhancing anchoring of the device 200 within the tissue. In addition, the first plurality of lobes 212 and/or the second plurality of lobes 222 may conform to a first tissue surface and a second tissue surface, respectively, such that tissue erosion is lessened and the first plurality of lobes 212 and/or the second plurality of lobes 222 react and move along with forces change the topography of the tissue.

In certain instances and as shown, the opening 250 through the device 200 includes a circumference that approximates a circle in shape. The diverging elements 240 cross over one another at certain locations in the central portion 230 such that a boundary or outer circumference of the opening 250 is approximately circular in shape. The diverging elements 240 may form a polygonal, structure, perimeter or boundary that approximates a circle. For example, the diverging elements 240 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal structure, perimeter or boundary that approximates a circle in a deployed configuration. The opening 250 approximating having a perimeter or boundary that approximates a circle in shape may facilitating collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the opening 250 in the deployed configuration. In the deployed configuration, the first frame portion 210 may be deployed on one side of a tissue structure and the second frame portion 220 may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C.

FIG. 3 is a top view of a first side of an implantable medical device 300, in accordance with an embodiment. As shown, the first frame portion 310 includes three lobes (e.g., a first lobe 312a, a second lobe 312b, and a third lobe 312c). The lobes may be spaced an equal distance apart from one another as shown such that each of the lobes are separate from one another. For example, each of the first, second, and third lobes 312a, 312b, 312c can move independently of one another to conform to the anatomy of the patient when the device 300 is in the deployed configuration.

Though not shown in FIG. 3, the second frame portion 320 can have the same or a different number of lobes as the first frame portion 310. For example, in some instances, the first and second frame portions 310, 320 each have three lobes. In other instances, the first frame portion 310 may include three lobes while the second frame portion 320 includes two, four, five or more lobes. In some instances, the first frame portion 310 can have lobes that are larger, smaller, and/or a different shape than the lobes of the second frame portion 320.

FIG. 4 is a top view of a first side of another implantable medical device 400, in accordance with an embodiment. As shown, the first frame portion 410 includes three lobes (e.g., a first lobe 412a, a second lobe 412b, and a third lobe 412c) and an inner frame portion 414. Each of the lobes 412a, 412b, and 412c may be attached to the inner frame portion 414 such that the lobes are equally spaced around the inner frame portion 414. In some instances, the lobes may be attached to the inner frame portion 414 and/or to adjacent lobes at attachment points 416a, 416b, and 416c. For example, in some instances, the first lobe 412a is attached to the second lobe 412b at attachment point 416a, the second lobe 412b is attached to the third lobe 412c at attachment point 416b, and the third lobe 412c is attached to the first lobe 412a at attachment point 416c. Although FIG. 4 is described with reference to three lobes and three attachment points, the first frame portion 410 can have any number of lobes and respective attachment points as desired. The first frame portion 410 and the second frame portion 420 are formed by diverging elements of a continuous or contiguous frame. The first frame portion 410 and the second frame portion 420 may be formed of a cut-tube, wound wire, or other similar structure.

Though not shown in FIG. 4, the second frame portion 420 can have the same or a different number of lobes as the first frame portion 410. For example, in some instances, the first and second frame portions 410, 420 each have three lobes. In other instances, the first frame portion 410 may include two, three lobes while the second frame portion 420 includes two, four, five or more lobes. In some instances, the first frame portion 410 can have lobes that are larger, smaller, and/or a different shape than the lobes of the second frame portion 420.

In certain instances, portions of the device 400 may include covering material as described in detail above with reference to FIG. 2. As discussed with reference to FIG. 2, the covering material may be configured to inhibit tissue ingrowth (e.g., within the inner frame portion 414 through the device 400). In addition, the first frame portion 410 and/or the second frame portion 420 may conform to a first tissue surface and a second tissue surface, respectively, such that tissue erosion is lessened and the first frame portion 410 and/or the second frame portion 420 react and move along with forces change the topography of the tissue.

In certain instances and as shown, the inner frame portion 414 through the device 400 includes a circumference that approximates a circle in shape. The inner frame portion 414 may form a polygonal structure, perimeter or boundary that approximates a circle. For example, the inner frame portion 414 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal perimeter or boundary that approximates a circle in a deployed configuration. The inner frame portion 414 approximating having a perimeter or boundary that approximates a circle in shape may facilitating collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the inner frame portion 414 in the deployed configuration. In the deployed configuration, one or more of the lobes 412a, 412b, 412c may be deployed on one side of a tissue structure and other ones of the lobes 412a, 412b, 412c may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C. The inner frame portion 414 may provide a lumen through with fluid may flow and may also hold open the tissue.

FIG. 5 is a top view of a first side of another implantable medical device 500, in accordance with an embodiment. As shown, the first frame portion 510 includes three lobes (e.g., a first lobe 512a, a second lobe 512b, and a third lobe 512c) and an inner frame portion 514. Each of the lobes 512a, 512b, and 512c may be attached to the inner frame portion 514 such that the lobes are equally spaced around the inner frame portion 514. In some instances, the lobes may be attached to the inner frame portion 514 and/or to adjacent lobes at attachment points 516a, 516b, and 516c. For example, in some instances, the first lobe 512a is attached to the second lobe 512b at attachment point 516a, the second lobe 512b is attached to the third lobe 512c at attachment point 516b, and the third lobe 512c is attached to the first lobe 512a at attachment point 516c. Although FIG. 5 is described with reference to three lobes and three attachment points, the first frame portion 510 of the device 500 can have any number of lobes and respective attachment points as desired.

The inner frame portion 514 can be any shape as desired. For example, in some instances, the inner frame portion 514 is substantially circular (e.g., as shown in FIG. 4) or substantially triangular (FIG. 5). In some instances, the inner frame portion 514 can define inner lobes 514a, 514b, and 514c, which may extend into the first, second and third lobes 512a, 512b, 512c to define the shape of the inner frame portion 514.

Though not shown in FIG. 5, the second frame portion 520 can have the same or a different number of lobes as the first frame portion 510. For example, in some instances, the first and second frame portions 510, 520 each have three lobes. In other instances, the first frame portion 510 may include three lobes while the second frame portion 520 includes two, four, five or more lobes. In some instances, the first frame portion 510 can have lobes that are larger, smaller, and/or a different shape than the lobes of the second frame portion 520.

In certain instances, the device 500 may include stiffeners 518a, 518b, 518c. The stiffeners 518a, 518b, 518c are arranged inside inner lobes 514a, 514b, and 514c (and may be included in any of the lobes of devices discussed herein. The stiffeners 518a, 518b, 518c form diamond cells in the inner lobes 514a, 514b, and 514c that collapse and open during load and deployment of the device 500 in a catheter. The stiffeners 518a, 518b, 518c may enhance radial strength during deployment and facilitate arrangement of the device 500 in a deployed and intended shape.

In certain instances and as shown, an opening 550 through the device 500 includes a circumference that approximates a circle in shape. A boundary or outer circumference of the opening 550 is approximately circular in shape. The first frame portion 510 and/or the second frame portion 520, when deployed, may form a polygonal structure, perimeter or boundary for the opening 550 that approximates a circle. For example, the opening 550 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal structure, perimeter or boundary that approximates a circle in a deployed configuration. The opening 550 approximating having a perimeter or boundary that approximates a circle in shape may facilitating collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the opening 550 in the deployed configuration. In the deployed configuration, the first frame portion 510 may be deployed on one side of a tissue structure and the second frame portion 520 may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C. The first frame portion 510 and the second frame portion 520 are formed by diverging elements of a continuous or contiguous frame. The first frame portion 510 and the second frame portion 520 may be formed of a cut-tube, wound wire, or other similar structure.

FIG. 6 is a top view of a first side of another implantable medical device 600, in accordance with an embodiment. As shown, the first frame portion 610 includes two lobes (e.g., a first lobe 612a and a second lobe 612b). A first inner frame portion 614a of the first lobe 612a and a second inner frame portion 614b of the second lobe 614b define the opening 650. The opening 650 may be any shape as desired. However, the shape of the opening 650 generally depends upon the shape of the first and second lobes 612a, 612b. For example, in some instances, the opening 650 may be substantially ovular, rectangular or oblong in shape, while in other instances, the opening 650 can be more circular in shape. The first frame portion 610 and the second frame portion 620 may be formed by diverging elements of a continuous or contiguous frame. The first frame portion 610 and the second frame portion 620 may be formed of a cut-tube, wound wire, or other similar structure.

The first and second lobes 612a, 612b may be integral with one another. For example, the first and second lobes 612a, 612b may be unitary such that the lobes are formed out of a single wire. In some instances, the first lobe 612a and the second lobe 612b may be formed separately from one another. For example, the first lobe 612a may be formed of a first wire and the second lobe 612b may be formed of a second wire, and the lobes may be attached at first and second attachment points 616a, 616b, as shown in FIG. 6.

Though not shown in FIG. 6, the second frame portion 620 can have the same or a different number of lobes as the first frame portion 610. For example, in some instances, the first and second frame portions 610, 620 each have three lobes. In other instances, the first frame portion 610 may include three lobes while the second frame portion 620 includes two, four, five or more lobes. In some instances, the first frame portion 610 can have lobes that are larger, smaller, and/or a different shape than the lobes of the second frame portion 620.

In certain instances, portions of the first frame portion 610 and/or the second frame portion 620 may include a covering material. The covering material may be configured to inhibit tissue ingrowth (e.g., within the opening 650 through the device 600). In addition, portions of the covering material arranged on the first frame portion 610 and/or the second frame portion 620 may be configured to facilitate tissue ingrowth to enhancing anchoring of the device 600 within the tissue. In addition, the lobes of the first frame portion 610 and the second frame portion 620 may conform to a first tissue surface and a second tissue surface, respectively, such that tissue erosion is lessened and the lobes react and move along with forces change the topography of the tissue. In the deployed configuration, the first frame portion 610 may be deployed on one side of a tissue structure and the second frame portion 620 may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C.

FIG. 7 is a perspective view of another implantable medical device 700, in accordance with an embodiment. The device 700 is shown in the delivery configuration with the first frame portion 710 and the second frame portion 720 folded in upon themselves to facilitate compaction of the device 700 for delivery to the desired treatment location. As shown, each side of the device 700 includes two lobes. For example, the first frame portion 710 includes a first lobe 712a and a second lobe 712b, and the second frame portion 720 includes a first lobe 722a and a second lobe 722b. The first and second frame portions 710, 720 are connected to one another at diverging points 742a and 742b to form a central portion 730 defining the opening 750.

One or more frame portions of the device 700 can include eyelets 790 to help facilitate delivery of the device. For example, each of the lobes of the first and/or second frame portions 710, 720 can include one or more eyelets 790. During delivery of the device 700, delivery lines could be threaded through the eyelets 790, for example, and tensioned to fold and/or compress the first and second frame portions 710, 720 into the delivery configuration. The eyelets 790 enable loading into a delivery catheter by interacting with tethers, wires, or other similar structures. The device 700 may be drawn into the catheter by the eyelets 790 and collapsed, for example, into the shape shown. In certain instances, the device 700 may include a post, ball, or an encapsulated frame element in place of the eyelets 790.

Once the device 700 is positioned at the desired treatment location, the first and second frame portions 710, 720 can be deployed (e.g., tension applied to the device 700 may be released) to release the lobes toward the septum of the patient (e.g., the first and second lobes 712a, 712b of the first frame portion 710 will release against the first side of the septum and the first and second lobes 722a, 722b of the second frame portion 720 will release against the second side of the septum).

FIG. 8A is an image of a first side of an implantable medical device 800 deployed at a desired treatment location, in accordance with an embodiment. FIG. 8B is an image of a second side of the implantable medical device 800 of FIG. 8A deployed at the desired treatment location, in accordance with an embodiment. As shown in FIG. 8A, the first frame portion 810 includes a first lobe 812a and a second lobe 812b. The second frame portion 820 (FIG. 8B) also includes a first lobe 822a and a second lobe 822b. In some instances, the first lobe 812a of the first frame portion 810 and the first lobe 822a of the second frame portion 820 are contiguous with one another. For example, the first lobes 812a, 822a are formed of a single, unitary wire that spans the septum and forms at least part of the central portion 830 of the device 800. The second lobe 812b of the first frame portion 810 and the second lobe 822b of the second frame portion 820 are also contiguous with one another. For example, the second lobes 812a, 822a are formed of a single, unitary wire that spans the septum and forms at least part of the central portion 830 of the device 800. As shown, the second frame portion 820 can have a different shape and size than the first frame portion 810. For example, in certain instances, the lobes 822a, 822b of the second frame portion 820 may have different shapes and/or sizes than the lobes 812a, 812b of the first frame portion 810.

Each of the first lobes 812a, 822a and the second lobes 812b, 822b are connected to one another at diverging points 842a, 842b to form a central portion 830 defining the opening 850. As shown, the opening 850 is generally ovular or oblong in shape. However, the opening 850 can be any shape as desired depending upon the shape and/or orientation of the first and second frame portions 810, 820 and the number of diverging points 842 in the central portion 830.

FIG. 9A is an image of an implantable medical device 900, in accordance with an embodiment. As shown, the device 900 is formed in a flat, 2-dimensional configuration. The first frame portion 910 includes two lobes (e.g., a first lobe 912a and a second lobe 912b). The second frame portion 920 is in the same plane as the first frame portion 910. As shown, the second frame portion 920 also includes two lobes (e.g., the first lobe 922a and second lobe 922b). In some instances, the first lobe 912a of the first frame portion 910 and the first lobe 922a of the second frame portion 920 are contiguous with one another. For example, the first lobes 912a, 922a are formed of a single, unitary wire. The second lobe 912b of the first frame portion 910 and the second lobe 922b of the second frame portion 920 are also contiguous with one another. For example, the second lobes 912a, 922a are formed of a single, unitary wire. As shown, the second frame portion 920 can have a different shape and/or size than the first frame portion 910. For example, the lobes 912a, 912b of the first frame portion may be larger and more elongate in shape than the lobes 922a, 922b of the second frame portion 920, which are smaller. Larger lobes 912a, 912b on one side (e.g., the left side) of the device 900 may prevent migration or dislodgement because pressure may be greater on the left side of the heart. The larger lobe 912a, 912b on the left side may absorb the higher pressure of the left side of the heart. The first frame portion 910 and the second frame portion 920 may be formed by diverging elements of a continuous or contiguous frame. The first frame portion 910 and the second frame portion 920 may be formed of a cut-tube, wound wire, or other similar structure.

FIG. 9B is an image of a first side of the implantable medical device 900 of FIG. 9A including a covering material 970, in accordance with an embodiment. In some instances, the first frame portion 910 includes the covering material 970 positioned over each of the lobes (e.g., the first lobe 912a and the second lobe 912b). The covering material 970 can be, for example, a membrane configured to promote tissue ingrowth to cover at least a portion of the first frame portion 910. The second frame portion 920 may or may not include the covering material 970.

FIG. 9C is an image of the second side of the implantable medical device 900 of FIG. 9A in the deployed configuration, in accordance with an embodiment. As shown in FIG. 9A, the first frame portion 910 includes the first lobe 912a and a second lobe 912b. The second frame portion 920 (FIG. 9B) also includes the first lobe 922a and a second lobe 922b. Each of the first lobes 912a, 922a and the second lobes 912b, 922b are connected to one another at diverging points 942a, 942b, 942c, 942d to form a central portion 930 defining the opening 950. As shown, the opening 950 is generally ovular or oblong in shape. However, the opening 950 can be any shape as desired depending upon the shape and/or orientation of the first and second frame portions 910, 920 and the number of diverging points 942 in the central portion 930.

In certain instances, portions of the covering material 970 may be configured to inhibit tissue ingrowth (e.g., within the opening 950 through the device 200). In addition, portions of the covering material 970 arranged on the first frame portion 910 and/or the second frame portion 920 may be configured to facilitate tissue ingrowth to enhancing anchoring of the device 900 within the tissue. In addition, each of the lobes of the first frame portion 910 and/or the second frame portion 920 may conform to a first tissue surface and a second tissue surface, respectively, such that tissue erosion is lessened and the lobes of the first frame portion 910 and/or the second frame portion 920 react and move along with forces change the topography of the tissue.

In certain instances and as shown, the opening 950 through the device 900 includes a circumference that approximates a circle in shape. A boundary or outer circumference of the opening 950 is approximately circular in shape. The first frame portion 910 and/or the second frame portion 920, when deployed, may form a polygonal structure, perimeter or boundary for the opening 950 that approximates a circle. For example, the opening 950 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal structure, perimeter or boundary that approximates a circle in a deployed configuration. The opening 950 approximating having a perimeter or boundary that approximates a circle in shape may facilitating collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the opening 950 in the deployed configuration.

FIG. 10A is an image of an implantable medical device 1000, in accordance with an embodiment. As shown, in some instances, both the first frame portion 1010 and second frame portion 1020 can include a covering material 1070. In certain instances, the covering material 1070 may be arranged on at least a portion of the first frame portion 1010 and/or the second frame portion 1020 and may span the central portion 1030. The first frame portion 1010 and second frame portion 1020, when covered with the covering material 1070, may form a first petal and a second petal respectively. As shown in FIG. 10A, the first frame portion 1010 and second frame portion 1020, when covered with the covering material 1070 to form petals, can be configured to flatten or longitudinally shorten. For example, the central portion 1030 (FIG. 10B) of the device can be configured to longitudinally shorten and compress such that the first and second frame portions 1010, 1020 are substantially flush with one another (e.g., with minimal separate between the first frame portion 1010 and second frame portion 1020).

As shown in FIG. 10B, the first frame portion 1010 and second frame portion 1020, when covered with the covering material 1070, may extend outwardly from the central portion 1030 to form cup like structures. In certain instances and as shown in FIG. 10B, the central portion 1030 can be configured to expand and lengthen longitudinally so that the device 1000 may span the septum of the patient.

FIG. 11 is an image of another implantable medical device 1100, in accordance with an embodiment. As shown, the first frame portion 1110 includes a first plurality of lobes 1112 arranged in an overlapping configuration. For example, each lobe of the first plurality of lobes 1112 at least partially overlaps an adjacent lobe. The second frame portion 1120 also includes a second plurality of lobes 1122 arranged in an overlapping configuration (e.g., each lobe of the second plurality of lobes 1122 at least partially overlaps an adjacent lobe).

FIG. 12 is an image of another implantable medical device 1200, in accordance with an embodiment. As shown, the device 1200 includes a first frame portion 1210 including a first plurality of lobes 1212. The first frame portion 1210 is connected to the second frame portion 1220 by diverging elements 1240 to form central portion 1230. The second frame portion 1220 includes a conduit portion 1280 extending from the second frame portion 1220 in the opposite direction of the first frame portion 1210. In some instances, the conduit portion 1280 can be positioned in a side branch of a vessel within the patient's body. In some instances, the conduit portion 1280 may form a lumen configured to facilitate fluid flow therethrough. In some instances, the conduit portion 1280 can also include a valve configured to control fluid flow through the lumen.

FIG. 13 is an image of a system for delivering the implantable medical device 1300 to the body of a patient, in accordance with an embodiment. As shown, the system may include a delivery device 1350 and a deployment mechanism 1360. In some instances, the deployment mechanism includes deployment lines configured to collapse the device 1300 into the delivery configuration.

In certain instances, the device 1300 can be loaded onto the delivery device 1350 such that the delivery device 1350 extends through the opening 1350 of the device 1300. The deployment lines can then be threaded through portions of the lobes of at least one of the first and second frame portions 1310, 1320. In some examples, the deployment lines may be threaded through eyelets formed in the lobes. The first and second frame portions are folded by advancement of the delivery device 1350 and collapsed into a low-profile delivery configuration.

The device 1300 can be delivered to the desired treatment location while in the delivery configuration. The first frame portion 1310 is then positioned on a first side of the septum and the second frame portion is positioned on a second side of the septum. Released of the second frame portion 1320 release is controlled by advancement and retraction of the delivery catheter.

In some instances, once deployed, the central portion 1330 of the device 1300 can be radially expanded or compressed to adjust the rate of fluid flow through the opening as desired.

FIG. 14A is an image of an implantable medical device 1400 and a deployment apparatus 1450, in accordance with an embodiment. FIG. 14B is an image of the implantable medical device 1400 with a first side deployed from the deployment apparatus 1450 shown in FIG. 14A, in accordance with an embodiment. As shown, the device 1400 is compressed into a delivery configuration and loaded into the deployment apparatus 1450 to be delivered to a desired treatment location within the patient's body.

In certain instances, the device 1400 is loaded into the deployment apparatus 1450 such that the device 1400 is completely contained within the deployment apparatus 1450, as shown in FIG. 14A.

The device 1400 can be delivered to the desired treatment location while in the delivery configuration. The first frame portion 1410 is then positioned on a first side of the septum and the second frame portion is positioned on a second side of the septum. In some instances, once deployed, the central portion 1430 of the device 1400 can be radially expanded or compressed to adjust the rate of fluid flow through the opening as desired. As described in detail above, the central portion 1430 may include a circumference that approximates a circle in shape. The central portion 1430 may form a polygonal structure, perimeter or boundary that approximates a circle. For example, the central portion 1430 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal perimeter or boundary that approximates a circle in a deployed configuration. The central portion 1430 approximating having a perimeter or boundary that approximates a circle in shape may facilitating collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the central frame portion 1430 in the deployed configuration.

FIG. 15A is an image of the implantable medical device 1500 (shown in FIG. 5), in accordance with an embodiment. As shown, the first frame portion 1510 includes three lobes (e.g., a first lobe 1512a, a second lobe 1512b, and a third lobe 1512c) and an inner frame portion 1514. Each of the lobes 1512a, 1512b, and 1512c may be attached to the inner frame portion 1514 such that the lobes are equally spaced around the inner frame portion 1514. In some instances, the inner frame portion 1514 serves as the second frame portion 1520, as shown and discussed with reference to FIG. 15D.

FIG. 15B is an image of the implantable medical device 1500 of FIG. 15A including a covering material 1570, in accordance with an embodiment. As shown, the covering material 1570 can be arranged over the first frame portion 1510. In some instances, the covering material 1570 may be attached to one or more of the first lobe 1512a, the second lobe 1512b, and the third lobe 1512c, as shown.

FIG. 15C is an image of a first side of the implantable medical device 1500, shown in FIG. 15A, including a covering material 1570, in accordance with an embodiment. As shown, in some instances, the covering material 1570 can be arranged over the opening 1530. Thus, the covering material 1530 may act to slow or occlude flow through the device 1500 as desired.

FIG. 15D is an image of a second side of the implantable medical device 1500, shown in FIG. 15C, in accordance with an embodiment. As shown, the covering material 1570 is arranged over the opening 1530. In various instances, the first, second, and third lobes 1522a, 1522b, 1522c of the second frame portion 1520 may or may not include the covering material 1570. For example, as shown in FIG. 15D, the covering material 1570 is arranged over the opening 1530 but not over the second frame portion 1520, while in other examples, the covering material 1570 may be arranged over both the opening 1530 and the second frame portion 1520.

FIG. 16A is an image of an implantable medical device 1600, in accordance with an embodiment. As shown, the device 1600 includes a first frame portion 1610 and a second frame portion 1620. The second frame portion 1620 includes first and second spokes 1622a and 1622b. In various instances, a covering material 1670 may be arranged over all or a portion of the first frame portion 1610 of the device 1600, as shown.

FIG. 16B is an image of a second configuration of the implantable medical device 1600 shown in FIG. 16A, in accordance with an embodiment. As shown, the device 1600 is sufficiently flexible such that it is compressible into a delivery configuration. Once positioned at the desired treatment location within the patient's body, the first frame portion 1610 of the device 1600 can be bent upon itself to force the spokes 1622a and 1622b radially outward, as shown in FIG. 16C. The first frame portion 1610 can be positioned on a first side of the septum while the second frame portion 1620 can be arranged on a second side of the septum. When the first frame portion 1610 is released back to its original configuration, the spokes 1622a, 1622b can retain the device 1600 in position in the patient's body.

FIG. 17A is an image of an implantable medical device 1700, in accordance with an embodiment. As shown, the first frame portion 1710 of the device 1700 may have no lobes, while the second frame portion 1720 has two or more lobes. For example, the second frame portion 1720 can have a first lobe 1722a and a second lobe 1722b. In some instances, the first frame portion 1710 and/or the second frame portion 1720 can include a covering material 1770. For example, the first frame portion 1710 can include the covering material 1770 as shown in FIG. 17B. However, in other examples, one or more lobes 1722a, 1722b of the second frame portion 1720 may include the covering material 1770, as desired.

FIG. 18 is an illustration of an implantable medical device 1800, in accordance with an embodiment. The implantable medical device 1800 includes a first frame portion 1810 and a second frame portion 1820 are formed by diverging elements of a continuous or contiguous frame. The first frame portion 1810 and the second frame portion 1820 may be formed of a cut-tube, wound wire, or other similar structure. As discussed in detail above, the first frame portion 1810 and the second frame portion 1820 may include a plurality of lobes and may be interconnected to one another.

In certain instances, the first frame portion 1810 and the second frame portion 1820 are formed by the plurality of diverging elements, which diverge from the first frame portion 1810 and the second frame portion 1820 to form a central frame 1850 that is configured to approximate a circular shape 1880 in a deployed configuration. As shown in FIG. 18, the diverging elements of the frame form a polygonal structure that is the central frame 1850. The number of sides of the polygonal structure that is the central frame 1850 approximate a circular shape 1880 in the deployed configuration.

In certain instances, the central frame 1850 is an opening through the device 1900 for fluid flow. The central frame 1850 forms a boundary or perimeter of that is approximately circular in shape. The first frame portion 1810 and/or the second frame portion 1820, when deployed, may form the central frame 1850 to include a polygonal structure, perimeter or boundary such that the circular shape 1880 is approximated. For example, the central frame 1850 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal structure, perimeter or boundary that approximates the circular shape 1880 in a deployed configuration. The central frame 1850 approximating having a perimeter or boundary that approximates a circle in shape may facilitating collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the central frame 1850 in the deployed configuration. In the deployed configuration, the first frame portion 1810 may be deployed on one side of a tissue structure and the second frame portion 1820 may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C.

FIG. 19 is an illustration of an implantable medical device 1900, in accordance with an embodiment. As shown, a first frame portion 1910 includes three lobes (e.g., a first lobe 1912a, a second lobe 1912b, and a third lobe 1912c) and an second frame portion 1920. Each of the lobes 1912a, 1912b, and 1912c may be attached to the second frame portion 1920 such that the lobes are equally spaced around the second frame portion 1920, which may also include a set of lobes 1914a, 1914b, and 1914c.

Though not shown in FIG. 19, the first frame portion 1910 and the second frame portion 1920 can have the same or a different number of lobes. For example, in some instances, the first and second frame portions 1910, 1920 each have three lobes. In other instances, the first frame portion 1910 may include two or three lobes while the second frame portion 1920 includes two, four, five or more lobes. In some instances, the first frame portion 1910 can have lobes that are larger, smaller, and/or a different shape than the lobes of the second frame portion 1920. The first frame portion 1910 and the second frame portion 1920 are formed by diverging elements of a continuous or contiguous frame. The first frame portion 1910 and the second frame portion 1920 may be formed of a cut-tube, wound wire, or other similar structure.

In certain instances and as shown, an opening 1950 through the device 1900 includes a circumference that approximates a circle in shape. A boundary or outer circumference of the opening 1950 is approximately circular in shape. The first frame portion 1910 and/or the second frame portion 1920, when deployed, may form a polygonal structure, perimeter or boundary for the opening 1950 that approximates a circle. For example, the opening 1950 may include 8, 10, 12, 14, 16, 18, 20, 22, 24 or additional sides that form a polygonal structure, perimeter or boundary that approximates a circle in a deployed configuration. The opening 1950 approximating having a perimeter or boundary that approximates a circle in shape may facilitate collapsing of the device to a delivery configuration while maintain hoop strength and lessen collapsing of the opening 1950 in the deployed configuration. In the deployed configuration, the first frame portion 1910 may be deployed on one side of a tissue structure and the second frame portion 1920 may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C.

In certain instances, portions of the first frame portion 1910 and/or the second frame portion 1920 may include a covering material 1970. The covering material 1970 may be configured to inhibit tissue ingrowth (e.g., within the opening 1950 through the device 600). In addition, portions of the covering material 1970 may be arranged on the first frame portion 1910 and/or the second frame portion 1920 between the lobes, as shown. In addition, the covering material 1970 between the lobes may be configured to facilitate tissue ingrowth to enhancing anchoring of the device 600 within the tissue. In the deployed configuration, the first frame portion 1910 may be deployed on one side of a tissue structure and the second frame portion 1920 may be deployed on another side of a tissue structure (e.g., as shown in FIGS. 9B-C.

The devices discussed herein may include a sensor integrated into the respective frame component, for example, for continuous monitoring of various hemodynamic parameters such as pressure, among other parameters, within the patient's body. For example, an antenna or inductor may be wrapped around the perimeter of one of the first and second frame components 110, 120 and the sensor may be attached to the inductor. The sensor may be configured to, for example, sense physiologic properties, such as hemodynamics, biomarkers, sound, pressure, and electrolytes that may be important in diagnosing, monitoring, and/or treating heart disease, heart failure, and/or other cardiovascular disease states.

In certain instances, the devices discussed herein may be capable of delivering a drug to the desired treatment location within the patient's body. For example, the devices may be capable of eluting a drug configured to modulate tissue response. In certain instances, the devices may be coated with a therapeutic coating, drug eluting material or other therapeutic material. In one specific example, the devices can be coated with heparin to facilitate thromboresistance and patency of the devices. Alternatively, or additionally, the devices may include paclitaxel (to modulate tissue/cellular response).

In certain instances, the heparin coating. The heparin coating is utilized to bind heparin molecules to the membrane or covering material. For further reference regarding a heparin coated membrane or covering material, reference may be made to U.S. Pat. No. 6,461,665 (“Scholander”) for the specific teachings of antithrombogenic activity of surface immobilized heparin, which is incorporated herein by reference. In certain instances, the heparin coating may be CARMEDA® BioActive Surface (CBAS® Heparin Surface).

In certain instances, the heparin coating may be applied to the membrane or covering material in one or more layers. The chemical constituents of the covering material in each layer can be the same or different. In some instances, the covering material is cross-linked to itself or other covering materials in other layers. The cross-linking bonds can be covalent or ionic. The heparin covering may form at least one layer on at least a portion of the membrane or covering material and may cross-link to itself or other layers of the covering. The cross-linking can be covalent, ionic, or both. For reference regarding the application of layers of heparin to the membrane or covering material reference may be made to U.S. Pat. No. 9,399,085 (Cleek et al.), which is incorporated herein by reference.

Suitable membrane materials for the membrane or covering material include, but are not limited to, polymers such as olefin, PEEK, polyamide, polyurethane, polyester, such as polyethylene terephthalate (PET), polyethylene, polypropylene, polyurethane, silicone, fluorinated ethylene propylene (FEP), polytetrafluoroethylene (PTFE), expanded polytetrafluoroethylene (ePTFE), and fluoroelastomers, such as tetrafluoroethylene/polymethylvinylether (TFE/PMVE) copolymers. In certain instances, the membrane or covering material may include is the elastomeric material (e.g., TFE/PMVE).

In some embodiments, bioresorbable or bioabsorbable materials may be used, for example a bioresorbable or bioabsorbable polymer. In some embodiments, the membrane can comprise a fluoropolymer, such as described in one or more of U.S. Pat. Nos. 7,049,380; 7,462,675; and 8,048,440, the contents of which are each incorporated by reference herein. In some embodiments, the membrane can comprise Dacron, polyolefins, carboxy methylcellulose fabrics, polyurethanes, or other woven or film elastomers. In some embodiments, the membrane or covering material can include knits or fibers. The membrane or covering material may be woven or non-woven in various embodiments including wires for example. In some embodiments, the membrane or covering material may be formed of a combination and/or copolymer of fluoropolymers or blends thereof.

Examples of synthetic polymers (which may be used as a membrane component) include, but are not limited to, nylon, polyacrylamide, polycarbonate, polyformaldehyde, polymethylmethacrylate, polytetrafluoroethylene, polytrifluorochlorethylene, polyvinylchloride, polyurethane, elastomeric organosilicon polymers, polyethylene, polypropylene, polyurethane, polyglycolic acid, polyesters, polyamides, their mixtures, blends and copolymers are suitable as a membrane material.

In some embodiments, the membrane is configured to inhibit, filter, modulate, or substantially modulate the passage of fluids and/or materials (such as blood and/or thrombus) through the membrane. In some embodiments, the membrane is configured to induce rapid tissue ingrowth therein. In an embodiment, the membrane provides for a blood or body fluid impermeable membrane that occludes the flow of blood or bodily fluids through the membrane yet promotes the ingrowth and endothelialization. The membrane can have a microporous structure that provides a tissue ingrowth scaffold for durable occlusion and supplemental anchoring strength of frames. In some embodiments, the membrane may be a porous member. Pores of the membrane may be sized to substantially, or in some examples completely, help prevent passage of blood, other bodily fluids, and emboli. In some implementations, the membrane prevents or substantially prevents passage of blood, other bodily fluids, thrombi, emboli, or other bodily materials through the membrane.

Nitinol (NiTi) may be used as the material of the frames discussed herein. In other instances, the frames may be formed from other materials such as stainless steel, L605 steel, polymers, MP35N steel, polymeric materials, Pyhnox, Elgiloy, or any other appropriate biocompatible material, and combinations thereof, can be used as the material of the frames. The super-elastic properties and softness of NiTi may enhance the conformability of the frames. In addition, NiTi can be shape-set into a desired shape. That is, NiTi can be shape-set so that the frame tends to self-expand into a desired shape when the frames is unconstrained, such as when the frame is deployed out from a delivery system. More specifically, the frame (made of NiTi) may have a spring nature that allows the frame to be elastically collapsed or “crushed” to a low-profile delivery configuration for loading in a delivery system, and then to reconfigure to the expanded configuration upon emergence from the delivery system. The frames, discussed herein, may be generally conformable, fatigue resistant, and elastic such that the frames may conform to the topography of the surrounding tissue when the occlusive device is deployed in a patient. In certain embodiments, bioresorbable or bioabsorbable materials may be used for the frame or a portion thereof, including for example, a bioresorbable or bioabsorbable polymer.

The membrane components, as discussed herein, may be attached to the self-expanding frame components by using a coupling member that is generally a flat ribbon or tape having at least one generally flat surface. In certain instances, the tape member is made from expanded PTFE (ePTFE) coated with an adhesive. The adhesive may be a thermoplastic adhesive. In certain instances, the thermoplastic adhesive may be fluorinated ethylene propylene (FEP). More specifically, an FEP-coated side of the ePTFE may face toward and contacts an exterior surface of the self-expanding frame components and membrane component, thus attaching the self-expanding frame components to the membrane component. Materials and method of attaching frame components to the membrane is discussed in U.S. Pat. No. 6,042,605 to Martin, incorporated by reference herein for all purposes.

In addition, nitinol (NiTi) may be used as the material of the frame or stent (and any of the frames discussed herein), but other materials such as, but not limited to, stainless steel, L605 steel, polymers, MP35N steel, polymeric materials, Pyhnox, Elgiloy, or any other appropriate biocompatible material, and combinations thereof, can be used as the material of the frame. The super-elastic properties and softness of NiTi may enhance the conformability of the stent. In addition, NiTi can be shape-set into a desired shape. That is, NiTi can be shape-set so that the frame tends to self-expand into a desired shape when the frame is unconstrained, such as when the frame is deployed out from a delivery system.

A variety of materials variously metallic, super elastic alloys, such as Nitinol, are suitable for use in these frame components. Primary requirements of the materials are that they be suitably springy even when fashioned into very thin sheets or small diameter wires. Various stainless steels which have been physically, chemically, and otherwise treated to produce high springiness are suitable as are other metal alloys such as cobalt chrome alloys (e.g., ELGILOY®), platinum/tungsten alloys, and especially the nickel-titanium alloys (e.g., Nitinol).

The invention of this application has been described above both generically and with regard to specific embodiments. It will be apparent to those skilled in the art that various modifications and variations can be made in the embodiments without departing from the scope of the disclosure. Thus, it is intended that the embodiments cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

Claims

1. An implantable medical device, comprising:

a first frame portion having at least three lobes;
a second frame portion arranged within the first frame portion, wherein the first frame portion and the second frame portion are coplanar with one another within a plane when the device is in an unconstrained configuration, wherein the plane is orthogonal to a longitudinal axis of the implantable medical device, and wherein at least a portion of the first and second frame portions are nonplanar with one another when the device is in a delivery configuration; and
a plurality of diverging elements arranged between the first frame portion and the second frame portion, the plurality of diverging elements diverge from the first frame portion and the second frame portion to form a central frame with at least six diverging points in a deployed configuration.

2. The device of claim 1, wherein the first frame portion and the second frame are contiguous with one another.

3. The device of claim 1, wherein the central frame defines an opening that is hexagonal in shape when the device is in a deployed configuration.

4. The device of claim 1, wherein the first frame portion is located on a first side of a septum, the second frame portion is located on a second side of the septum, and the plurality of diverging elements form a fluid flow path therethrough.

5. The device of claim 4, wherein the first and second frame portions are sufficiently flexible to conform to an anatomy of the septum.

6. The device of claim 1, wherein the second frame portion includes at least three lobes.

7. The device of claim 1, wherein the first frame portion has a first geometry and the second frame portion has a second geometry that is different from the first geometry.

8. The device of claim 1, wherein the first frame portion includes six lobes.

9. The device of claim 1, wherein each of the lobes of the second frame portion comprises an eyelet configured to aid in delivery of the device.

10. The device of claim 1, further comprising a covering material arranged on at least a portion of the device.

11. The device of claim 10, wherein the first frame portion includes the covering material and the second frame portion is free of the covering material.

12. The device of claim 11, wherein the covering material includes expanded polytetrafluoroethylene (ePTFE).

13. The device of claim 1, wherein the first frame portion and the second frame portion are unitary such that the device is formed of a single wire.

14. The device of claim 1, further comprising at least one of a coating of heparin to facilitate thromboresistance and patency of the device and a coating of paclitaxel to modulate tissue/cellular response.

15. The device of claim 1, wherein the longitudinal axis extends through a center of a lumen defined by the implantable medical device and the plane extends through a portion of the lumen.

16. The device of claim 1, wherein the at least three lobes extend perpendicularly to the longitudinal axis in the unconstrained configuration.

Referenced Cited
U.S. Patent Documents
5276276 January 4, 1994 Gunn
5334217 August 2, 1994 Das
5683411 November 4, 1997 Kavteladze et al.
5824055 October 20, 1998 Spiridigliozzi et al.
5944738 August 31, 1999 Amplatz et al.
6042602 March 28, 2000 Wells
6042605 March 28, 2000 Martin et al.
6077291 June 20, 2000 Das
6080182 June 27, 2000 Shaw et al.
6461665 October 8, 2002 Scholander
6616675 September 9, 2003 Evard et al.
6911037 June 28, 2005 Gainor et al.
6926670 August 9, 2005 Rich et al.
7001409 February 21, 2006 Amplatz
7049380 May 23, 2006 Chang et al.
7128073 October 31, 2006 Van et al.
7236821 June 26, 2007 Cates et al.
7462675 December 9, 2008 Chang et al.
7871659 January 18, 2011 Cook et al.
7887562 February 15, 2011 Young et al.
7901702 March 8, 2011 Schwarz
8021331 September 20, 2011 Herweck et al.
8043360 October 25, 2011 Mcnamara et al.
8048440 November 1, 2011 Chang et al.
8091556 January 10, 2012 Keren et al.
8480707 July 9, 2013 Pavcnik et al.
8545525 October 1, 2013 Surti et al.
8696693 April 15, 2014 Najafi et al.
8715300 May 6, 2014 Najafi et al.
8728103 May 20, 2014 Surti et al.
9241695 January 26, 2016 Peavey et al.
9314556 April 19, 2016 Tuseth
9358371 June 7, 2016 Mcnamara et al.
9399085 July 26, 2016 Cleek et al.
9456812 October 4, 2016 Finch et al.
9545300 January 17, 2017 Cully et al.
9554786 January 31, 2017 Carley et al.
9629715 April 25, 2017 Nitzan et al.
9636094 May 2, 2017 Aurilia et al.
9649481 May 16, 2017 Sadanand
9681948 June 20, 2017 Levi et al.
9757107 September 12, 2017 Mcnamara et al.
9775591 October 3, 2017 Delgado et al.
9861346 January 9, 2018 Callaghan
9878162 January 30, 2018 Mika et al.
9949728 April 24, 2018 Cahill
10806458 October 20, 2020 Todd
10925706 February 23, 2021 Eigler et al.
20020077555 June 20, 2002 Schwartz
20020077556 June 20, 2002 Schwartz
20020169475 November 14, 2002 Gainor et al.
20020173742 November 21, 2002 Keren et al.
20030055344 March 20, 2003 Eigler et al.
20030139819 July 24, 2003 Beer et al.
20040049211 March 11, 2004 Tremulis et al.
20040063805 April 1, 2004 Pacetti et al.
20040073242 April 15, 2004 Chanduszko
20050038351 February 17, 2005 Starobin et al.
20050049675 March 3, 2005 Wallace
20050148925 July 7, 2005 Rottenberg et al.
20050283231 December 22, 2005 Haug et al.
20060008500 January 12, 2006 Chavan et al.
20060009800 January 12, 2006 Christianson et al.
20060079736 April 13, 2006 Chin et al.
20060100687 May 11, 2006 Fahey et al.
20060116590 June 1, 2006 Fayram et al.
20060198866 September 7, 2006 Chang et al.
20060271116 November 30, 2006 Stahmann et al.
20070032734 February 8, 2007 Najafi et al.
20070118039 May 24, 2007 Bodecker et al.
20070118213 May 24, 2007 Loulmet
20070244518 October 18, 2007 Callaghan
20070282430 December 6, 2007 Thommen et al.
20080221551 September 11, 2008 Goodson et al.
20080249562 October 9, 2008 Cahill
20080262518 October 23, 2008 Freudenthal
20080269551 October 30, 2008 Annest et al.
20090024042 January 22, 2009 Nunez et al.
20090030331 January 29, 2009 Hochareon et al.
20090099640 April 16, 2009 Weng
20090221923 September 3, 2009 Uemura et al.
20090240427 September 24, 2009 Siereveld et al.
20090319037 December 24, 2009 Rowe et al.
20100049313 February 25, 2010 Alon et al.
20100069778 March 18, 2010 Bornzin et al.
20100094401 April 15, 2010 Kolbel et al.
20110071623 March 24, 2011 Finch et al.
20110071624 March 24, 2011 Finch et al.
20110098767 April 28, 2011 Sugimachi et al.
20110153010 June 23, 2011 Hanna
20110184439 July 28, 2011 Anderson et al.
20110257723 October 20, 2011 Mcnamara
20110295183 December 1, 2011 Finch et al.
20110295366 December 1, 2011 Finch et al.
20110303229 December 15, 2011 Najafi et al.
20120136385 May 31, 2012 Cully
20120265296 October 18, 2012 Mcnamara et al.
20130144379 June 6, 2013 Najafi et al.
20130165967 June 27, 2013 Amin et al.
20130178784 July 11, 2013 Mcnamara et al.
20130281988 October 24, 2013 Magnin et al.
20140012368 January 9, 2014 Sugimoto et al.
20140018911 January 16, 2014 Zhou et al.
20140107437 April 17, 2014 Pinsky
20140128795 May 8, 2014 Keren et al.
20140142617 May 22, 2014 Arsen et al.
20140200662 July 17, 2014 Eftel et al.
20140207153 July 24, 2014 Najafi et al.
20140214149 July 31, 2014 Kuraguntla et al.
20140222040 August 7, 2014 Park et al.
20140228683 August 14, 2014 Aoki et al.
20140343670 November 20, 2014 Bakis et al.
20140371843 December 18, 2014 Wilson et al.
20150039084 February 5, 2015 Levi et al.
20150142049 May 21, 2015 Delgado et al.
20150313596 November 5, 2015 Todd
20150313599 November 5, 2015 Johnson et al.
20160045165 February 18, 2016 Braido et al.
20160058452 March 3, 2016 Brenneman et al.
20160158000 June 9, 2016 Granada et al.
20160263299 September 15, 2016 Xu et al.
20160331566 November 17, 2016 Kheradvar et al.
20170028194 February 2, 2017 Bonner et al.
20170042705 February 16, 2017 Cook et al.
20170105711 April 20, 2017 Masters
20170106176 April 20, 2017 Taft et al.
20170135817 May 18, 2017 Tylis et al.
20170172766 June 22, 2017 Vong et al.
20170196673 July 13, 2017 Cully et al.
20170224323 August 10, 2017 Rowe et al.
20170281339 October 5, 2017 Levi et al.
20170319823 November 9, 2017 Yacoby et al.
20170358942 December 14, 2017 Pugh et al.
20180000580 January 4, 2018 Wallace et al.
20180008830 January 11, 2018 Kaiser
20180055629 March 1, 2018 Oba et al.
20180098772 April 12, 2018 Goldshtein et al.
20180126179 May 10, 2018 Haasl et al.
20180160917 June 14, 2018 Liu et al.
20180256865 September 13, 2018 Finch et al.
20180280667 October 4, 2018 Keren
20190130069 May 2, 2019 Li et al.
20190231510 August 1, 2019 Rafiee et al.
20190282178 September 19, 2019 Volosin et al.
20190374343 December 12, 2019 Lashinski et al.
20200038567 February 6, 2020 Siess et al.
20200069426 March 5, 2020 Conklin et al.
20200085378 March 19, 2020 Burnett et al.
20200196876 June 25, 2020 Minor et al.
20200196943 June 25, 2020 Minor et al.
20200196944 June 25, 2020 Minor et al.
20200197178 June 25, 2020 Vecchio
20210259839 August 26, 2021 Cole et al.
20210290214 September 23, 2021 Cole et al.
20240130624 April 25, 2024 Kanjickal et al.
20250186208 June 12, 2025 Chang et al.
Foreign Patent Documents
2995185 August 2018 CA
1819855 August 2006 CN
102271727 December 2011 CN
104414692 March 2015 CN
105473107 April 2016 CN
107411848 December 2017 CN
107847751 March 2018 CN
108289737 July 2018 CN
108451569 August 2018 CN
108472142 August 2018 CN
108697505 October 2018 CN
110536657 December 2019 CN
1264572 December 2002 EP
2020248 February 2009 EP
2637576 September 2013 EP
1355373 June 1974 GB
1506432 April 1978 GB
1509023 April 1978 GB
07-502918 March 1995 JP
2000-505316 May 2000 JP
2001-519694 October 2001 JP
2002-248105 September 2002 JP
2003-061917 March 2003 JP
2003-519542 June 2003 JP
2005-528181 September 2005 JP
2006-528023 December 2006 JP
2007-527742 October 2007 JP
2008-512139 April 2008 JP
2008-512211 April 2008 JP
2008-545471 December 2008 JP
2009-517137 April 2009 JP
2010-505481 February 2010 JP
2012-500665 January 2012 JP
2013-517890 May 2013 JP
2014-503246 February 2014 JP
2014-151049 August 2014 JP
2016-511656 April 2016 JP
2016-518948 June 2016 JP
2016-538094 December 2016 JP
2017-513545 June 2017 JP
2017-515631 June 2017 JP
2017-536857 December 2017 JP
2021-531097 November 2021 JP
93/13712 July 1993 WO
97/27898 August 1997 WO
98/42276 October 1998 WO
01/51123 July 2001 WO
2003/103476 December 2003 WO
2004/091411 October 2004 WO
2005/074367 August 2005 WO
2006/054343 May 2006 WO
2007/062299 May 2007 WO
2008/040555 April 2008 WO
2009/137755 November 2009 WO
2010/022138 February 2010 WO
2011/093941 August 2011 WO
2012/091809 July 2012 WO
2014/018977 January 2014 WO
2014/150106 September 2014 WO
2015/109027 July 2015 WO
2015/168501 November 2015 WO
2017/118738 July 2017 WO
2018/017900 January 2018 WO
2020/018697 January 2020 WO
Other references
  • Eigler et al., “Cardiac Unloading with an Implantable Interatrial Shunt in Heart Failure: Serial Observations in an Ovine Model of Ischemic Cardiomyopathy”, Structural Heart, vol. 1, No. (1-2), 2017, 'pp. 40-48.
  • Feldman et al., “Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure Rationale and Design of the Randomized Trial to Reduce Elevated Left Atrial Pressure in Heart Failure (Reduce LAP-HF I)”, Circulation Heart failure, vol. 9, No. 7, 2016, pp. 1-10.
  • Gregg et al., “Interatrial Shunting for Heart Failure The V-Wave Shunt”, Presentation at the Transcatheter Cardiovascular Therapeutics (TCT) Congress in Denver, Colorado, 2017, 18 pages.
  • Søndergaard et al., “Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure”, European Journal of Heart Failure, vol. 16, 2014, pp. 796-801.
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/068277, mailed on Mar. 25, 2020, 13 pages.
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/068280, mailed on Mar. 25, 2020, 12 pages.
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/068282, mailed on Mar. 25, 2020, 15 pages.
  • International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/068275, mailed on Jul. 1, 2021, 11 pages.
  • International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/068277, mailed on Jul. 1, 2021, 7 pages.
  • International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/068280, mailed on Jul. 1, 2021, 7 pages.
  • International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2019/068282, mailed on Jul. 1, 2021, 9 pages.
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/068275, mailed on Jun. 25, 2020, 16 pages.
  • Kapur NK et al. Mechanical circulatory support devices for acute right ventricular failure. Circulation. 2017; 136:314-326 (Year: 2017).
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/042248, mailed on Oct. 23, 2019, 18 pages.
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2019/042252, mailed on Oct. 21, 2019, 18 pages.
  • International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2021/013411, mailed on May 6, 2021, 11 pages.
  • Wei, X., Liu, X., Rosenzweig, A. What do we know about the cardiac benefits of exercise? Trends in Cardiovascular Medicine; 25(6) : 537-539. Aug. 2015 (Year: 2015).
  • Tanaka Hikaru, et al., “Shinzo No. Byouki to Chiryouaku”, [online], Aug. 23, 2006, Internet URL: https://web.archive.org/web/20060823022639/https://www.mnc.tohou.ac.jp/v-lab/shinkin/medicine/medicine-1-2-1.html.
  • Tanaka et al., “A Pharmaceutical agent for the heart and drugs”, Aug. 23, 2006, pp. 1-5.
Patent History
Patent number: 12691264
Type: Grant
Filed: Dec 10, 2019
Date of Patent: Jul 28, 2026
Patent Publication Number: 20200179663
Assignee: W. L. Gore & Associates, Inc. (Newark, DE)
Inventors: Tom R. McDaniel (Flagstaff, AZ), Edward E. Shaw (Flagstaff, AZ)
Primary Examiner: Kai H Weng
Application Number: 16/709,129
Classifications
Current U.S. Class: Material Placed On Opposed Sides Of Incision Or Wound (606/215)
International Classification: A61M 27/00 (20060101);